GLP-1s for Teens: What Parents Need to Know About the New Weight Management Options

Five Clinical Trials Are Changing Adolescent Obesity Treatment

If your teenager's doctor has mentioned GLP-1 therapy, you are not alone. Pediatric obesity affects approximately one in five adolescents in the United States, and a wave of clinical research is reshaping how physicians approach weight management in this age group.

Right now, five active or recently completed clinical trials are addressing the critical questions parents need answered: Does weight loss persist after treatment stops? Are these medications safe for developing bodies? Do dosing requirements differ for adolescents? What about bone health?

This guide walks through everything parents should know — the science, the safety data, and the practical considerations.

What Are GLP-1 Medications?

GLP-1 receptor agonists — the class of medications that includes semaglutide (Wegovy, Ozempic), liraglutide (Saxenda, Victoza), and exenatide (Bydureon) — work by mimicking a natural hormone your body produces after eating. This hormone signals fullness to the brain, slows stomach emptying, and helps regulate blood sugar.

Think of it as amplifying your teenager's natural "I am full" signal. Unlike older weight loss medications that worked through stimulant pathways, GLP-1s work through the body's own metabolic regulation systems.

For adolescents, these medications represent a fundamentally different approach. Instead of asking teenagers to fight biology through willpower alone, GLP-1 therapy addresses the hormonal and metabolic drivers of obesity at their source.

The Five Trials Every Parent Should Know About

1. STEP TEENS Weight Maintenance (NCT06571383)

What it tests: Whether semaglutide 2.4 mg helps adolescents aged 12–17 not just lose weight but keep it off over an extended period.

Why this matters: Weight maintenance is the hardest problem in adolescent obesity. Adult data shows that up to 70% of initial weight loss is regained within two years of stopping GLP-1 therapy. Adolescents face additional challenges — hormonal changes during puberty, social pressures around eating, and developing the habits that support long-term health.

This Phase 3 trial, sponsored by Novo Nordisk, is actively recruiting and addresses the most important real-world question parents ask: "Will this just be a temporary fix?"

2. Bydureon in Adolescents (NCT02794402)

What it tests: Exenatide (Bydureon) — a once-weekly GLP-1 — versus placebo in adolescents with obesity over six months.

Why this matters: Semaglutide gets most of the headlines, but exenatide has been studied in adolescents longer than any other GLP-1. This completed trial provides important data on whether the oldest GLP-1 option still has a role in adolescent treatment.

For some teenagers, exenatide may offer a gentler side effect profile while still producing meaningful weight reduction.

3. Dulaglutide vs Liraglutide Head-to-Head (NCT04829903)

What it tests: A direct comparison of two GLP-1 options — once-weekly dulaglutide versus daily liraglutide — in adolescents with obesity and type 2 diabetes who are already on metformin.

Why this matters: This trial answers a question parents and doctors face regularly: Is a weekly injection better than a daily one? Dosing frequency is not just about convenience — it directly affects whether a teenager will stay on therapy. A weekly injection may be easier to incorporate into a teenager's routine than a daily one.

4. Bone Metabolism in Adolescents on GLP-1 Therapy (NCT06903923)

What it tests: How GLP-1 therapy affects bone metabolism in adolescents and young adults aged 12–21.

Why this matters: This is one of the most important safety questions in pediatric GLP-1 therapy. The adolescent skeleton is still building peak bone mass — the maximum bone density a person will achieve in their lifetime. Any therapy that interferes with this process has lifelong consequences for fracture risk.

The trial is not yet recruiting, but its very existence signals that the medical community recognizes bone safety as a priority. We cover bone health in detail in our companion guide.

5. Liraglutide Safety and PK in Adolescents (NCT01789086)

What it tests: The safety, tolerability, and pharmacokinetics — how the drug moves through the body — of liraglutide in adolescents aged 12–17.

Why this matters: Adolescents are not "small adults." Their metabolism, hormone levels, and body composition differ from adults in ways that affect how medications work. This trial addresses the fundamental question of whether adolescent dosing should be the same as adult dosing.

Liraglutide was the first GLP-1 approved for adolescent obesity (FDA approval in 2020), and this pediatric-specific safety data provides the foundation for confident prescribing.

How the GLP-1 Options Compare

Feature	Semaglutide (Wegovy)	Liraglutide (Saxenda)	Exenatide (Bydureon)
Dosing frequency	Once weekly	Once daily	Once weekly
FDA approval for adolescents (12+)	Yes (2023)	Yes (2020)	Not specifically for obesity
Average weight loss	~15%	~10–12%	~8–10%
Clinical track record in adolescents	Growing	Strongest (since 2020)	Longest study history
Injection type	Weekly subcutaneous	Daily subcutaneous	Weekly subcutaneous
GI side effects	Moderate to common	Moderate	Generally milder

Common Concerns Parents Have

Is this safe for my teenager's developing body?

The available data is reassuring but incomplete. GLP-1 medications have been studied in thousands of adolescents across multiple trials, and the most common side effects are gastrointestinal — nausea, vomiting, diarrhea — which are typically manageable with slow dose titration and resolve over time.

More serious side effects are rare. The key areas where long-term data is still accumulating include bone health (being studied in the bone metabolism trial above) and the effects on growth and pubertal development. Current evidence does not suggest clinically significant concerns, but monitoring is appropriate.

Will my teenager need to be on this forever?

This is an honest and important question. Available data shows that when GLP-1 therapy is discontinued, most patients regain a significant portion of the weight they lost. For this reason, GLP-1 therapy is increasingly viewed as a chronic management tool — similar to how we think about blood pressure or cholesterol medications — rather than a short-term intervention.

However, the treatment window during adolescence also provides an opportunity. While on therapy, teenagers can establish healthier eating habits, physical activity routines, and metabolic patterns that may persist even if the medication dose is reduced or stopped later.

What about the cost?

Cost varies significantly depending on insurance coverage and whether you access branded or compounded formulations. Branded GLP-1 medications can cost $800–$1,400 per month, though many insurance plans now cover GLP-1 therapy for adolescents with obesity when prescribed according to FDA guidelines. Compounded formulations through physician-prescribed protocols are typically more affordable. Discussing coverage with your insurance provider and your prescribing physician is the best first step.

What Parents Can Do Now

Start the conversation with your teenager's doctor. If your adolescent has a BMI at or above the 95th percentile for their age and sex, or a BMI of 30 or higher, they may be a candidate for GLP-1 therapy. A pediatrician or adolescent medicine specialist can evaluate their individual situation.

Focus on the bigger picture. GLP-1 medications work best when paired with nutritional guidance, physical activity, and behavioral support. They are a tool — not a replacement — for healthy habits.

Stay informed about the evidence. The five clinical trials described above will continue to produce data over the coming months and years. Each new result adds to our understanding of how to use these medications safely and effectively in adolescents.

Ask about monitoring. A thoughtful treatment plan includes not just medication but also monitoring: growth velocity, pubertal development, labs, and — for long-term therapy — bone health assessment.

Getting Started with LuxeFit Wellness

At LuxeFit Wellness, we believe that adolescent obesity treatment should be evidence-based, safety-first, and family-centered. Our physician-prescribed protocols include comprehensive evaluation, individualized dosing, and ongoing monitoring — because the goal is not just weight loss, but lifelong metabolic health.

If you are exploring GLP-1 therapy for your teenager, the first step is a consultation with a licensed physician who can evaluate their candidacy, discuss the options, and design a personalized protocol.

Schedule a consultation today to learn whether a pediatric GLP-1 protocol is right for your family.

*Disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 receptor agonists require evaluation and prescription by a licensed healthcare provider. Individual results vary. Not all therapies discussed are FDA-approved for pediatric use. Always consult a qualified healthcare provider before starting, stopping, or changing any medication for your child.*

See our Semaglutide Alternatives in 2026: A Complete Patient Guide for a complete comparison of every semaglutide alternative.